Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
(ECCO-the European CanCer Organisation) Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. The 26th EORTC-NCI-AACR Symposium will hear that the combination of bevacizumab and erlotinib produced excellent response rates in patients with advanced papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2014 Category: Cancer & Oncology Source Type: news

Roche says Avastin approved in U.S. for type of ovarian cancer
ZURICH (Reuters) - Roche said on Monday that the U.S. health regulator approved its Avastin drug as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Roche’s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. (Source: Roche Media News)
Source: Roche Media News - November 17, 2014 Category: Pharmaceuticals Source Type: news

FDA approves Roche’s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer
Roche, today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - November 17, 2014 Category: Pharmaceuticals Source Type: news

Business Briefing: F.D.A. Approves Avastin as Ovarian Cancer Treatment
The Swiss drug maker Roche said on Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer. (Source: NYT Health)
Source: NYT Health - November 15, 2014 Category: Consumer Health News Authors: By THE ASSOCIATED PRESS Tags: Roche Holding AG RHHBY Other OTC Food and Drug Administration Avastin (Drug) Ovarian Cancer Source Type: news

FDA Approves Bevacizumab for Recurrent Ovarian CancerFDA Approves Bevacizumab for Recurrent Ovarian Cancer
Bevacizumab has received FDA approval for use in combination with chemotherapy in women with platinum-resistant, recurrent ovarian cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Avastin for Recurrent Ovarian Ca
(MedPage Today) -- Boosted overall and progression-free survival when added to paclitaxel. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 14, 2014 Category: American Health Source Type: news

Drug Combo Doesn ’ t Lengthen Glioblastoma Survival
Lomustine + bevacizumab may increase progression - free, but not overall, survival versus lomustine alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Journal, Source Type: news

Atezolizumab + Bevacizumab Shows Benefit in Met Renal CA
Progression - free survival benefit for patients with untreated metastatic renal cell carcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Nephrology, Oncology, Conference News, Source Type: news

France asks Roche for data on use of cancer drug Avastin in eye
PARIS (Reuters) - French medicine agency ANSM has written to Roche asking the Swiss drugmaker for information on off-label uses of its cancer drug Avastin, which ANSM wants to let doctors prescribe as a cheap alternative eye treatment. (Source: Reuters: Health)
Source: Reuters: Health - November 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy
This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.11/01/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 1, 2014 Category: Cancer & Oncology Source Type: news

Health refugees forced to sell up and move to England for life-saving care: Continuing our investigation into the terrifying state of the Welsh NHS - run by Labour for the past 15 years - which proves you can't trust Red Ed with your health
One pregnant woman travelled 55 miles in labour to avoid a Welsh maternity unit, while a cancer patient from Cardiff (pictured) had to the get life-prolonging drug Avastin in London. (Source: the Mail online | Health)
Source: the Mail online | Health - October 21, 2014 Category: Consumer Health News Source Type: news

Regeneron's Eylea Works Better vs Avastin and Lucentis in StudyRegeneron's Eylea Works Better vs Avastin and Lucentis in Study
Regeneron Pharmaceuticals said its drug Eylea (aflibercept) for diabetic macular edema produced significantly greater improvement in visual acuity from baseline to 52 weeks compared with Genentech's Avastin (bevacizumab) and Lucentis (ranibizumab). Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 21, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
TARRYTOWN, N.Y., Oct. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net)... Biopharmaceuticals, OphthalmologyRegeneron Pharmaceuticals, EYLEA, aflibercept, Diabetic Macular Edema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2014 Category: Pharmaceuticals Source Type: news

Regeneron's Eylea works better vs Avastin and Lucentis in study
(Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis. (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Protein Content in Compounded Bevacizumab Varies ConsiderablyProtein Content in Compounded Bevacizumab Varies Considerably
The protein concentration of bevacizumab prepared by U.S. compounding pharmacies for intravitreal injection shows significant variations, according to New York-based researchers. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 29, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Roche's investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone
Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC. Roche also presented monotherapy data for MPDL3280A in patients with mRCC who had been mostly pretreated. (Source: Roche Investor Update)
Source: Roche Investor Update - September 29, 2014 Category: Pharmaceuticals Source Type: news

Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab)
Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC. Roche also presented monotherapy data for MPDL3280A in patients with mRCC who had been mostly pretreated. (Source: Roche Investor Update)
Source: Roche Investor Update - September 29, 2014 Category: Pharmaceuticals Source Type: news

Gain from adding Roche's Avastin to immune drug unclear
MADRID (Reuters) - It is too early to say whether combining Roche's best-selling Avastin cancer drug with the company's experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumors. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Roche says Avastin prolongs life in breast cancer study
FRANKFURT (Reuters) - Swiss drugmaker Roche said its cancer drug Avastin helped women with a common form of breast cancer live longer without their disease worsening, when used in combination with chemotherapy drug Xeloda. (Source: Reuters: Health)
Source: Reuters: Health - September 25, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies
Roche today announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival (OS) and progression-free survival (PFS) in women with HER2-negative metastatic breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2014 Category: Pharmaceuticals Source Type: news

Bevacizumab's Role in Late-Stage Cervical CancerBevacizumab's Role in Late-Stage Cervical Cancer
Dr. Maurie Markman discusses the recent FDA approval of bevacizumab for recurrent or late-stage cervical cancer and weighs the benefits of the drug in this setting against its toxicity profile. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Risk Factors for Geographic Atrophy in the CATT TrialRisk Factors for Geographic Atrophy in the CATT Trial
The CATT results are discussed -- will they help ophthalmologists choose either bevacizumab or ranibizumab? Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 19, 2014 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news

Costly Eye Drug, Cheaper Alternative Have Similar Side EffectsCostly Eye Drug, Cheaper Alternative Have Similar Side Effects
Injecting Roche's cancer drug Avastin as a cheap eye treatment does not appear to increase deaths or serious side effects, according to an independent study that is likely to fuel a row over the medicine's unapproved use. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Costly eye drug and far cheaper alternative have similar side effects, says study
Injecting Roche's cancer drug Avastin as a cheap eye treatment does not appear to increase deaths or serious side effects, says study. (Source: The Economic Times)
Source: The Economic Times - September 15, 2014 Category: Consumer Health News Source Type: news

Costly eye drug and far cheaper alternative have similar side effects: study
LONDON (Reuters) - Injecting Roche's cancer drug Avastin as a cheap eye treatment does not appear to increase deaths or serious side effects, according to an independent study that is likely to fuel a row over the medicine's unapproved use. (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Avastin (bevacizumab) - Angiogenesis
The product of a joint development programme between Genentech and Roche, Avastin (bevacizumab) is a humanised monoclonal antibody (MAb) directed against vascular endothelial growth factor (VEGF), a pro-angiogenesis factor. (Source: Drug Development Technology)
Source: Drug Development Technology - September 9, 2014 Category: Pharmaceuticals Source Type: news

FOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal CancersFOLFIRI Plus Cetuximab vs Bevacizumab for Some Colorectal Cancers
In patients with KRAS exon 2 wild-type metastatic colorectal cancer (MCC) who received first-line FOLFIRI (fluorouracil, folinic acid and irinotecan), adding cetuximab rather than bevacizumab yielded longer overall survival. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche’s Avastin plus chemotherapy receives FDA approval to treat cervical cancer
Switzerland-based Roche has received approval from the US Food and Drug Administration (FDA) for its Avastin (bevacizumab), in combination with paclitaxel and cisplatin or paclitaxel and topotecan, to treat women with persistent, recurrent or metasta… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 18, 2014 Category: Pharmaceuticals Source Type: news

Avastin Approved for Late-Stage Cervical Cancer
Title: Avastin Approved for Late-Stage Cervical CancerCategory: Health NewsCreated: 8/15/2014 12:35:00 PMLast Editorial Review: 8/18/2014 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 18, 2014 Category: Cancer & Oncology Source Type: news

Bevacizumab Approved for Late-Stage Cervical Cancer (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH The FDA has approved bevacizumab (Avastin) for metastatic, persistent, or recurrent cervical cancer to be used in combination with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 18, 2014 Category: Primary Care Source Type: news

briefing: Drug Is Approved as Treatment for Cervical Cancer
The F.D.A. approved Avastin on Thursday for women with cervical cancer that is persistent, recurrent or has spread to other parts of the body. (Source: NYT Health)
Source: NYT Health - August 16, 2014 Category: Consumer Health News Authors: By THE ASSOCIATED PRESS Tags: Roche Holding AG RHHBY Other OTC Drugs (Pharmaceuticals) Southwest Airlines Company LUV NYSE Cervical Cancer Food and Drug Administration SeaWorld Entertainment Inc SEAS NYSE Ford Motor Co F NYSE Source Type: news

Avastin Wins FDA OK for Cervical Cancer
WASHINGTON (MedPage Today) -- The FDA has approved the angiogenesis inhibitor bevacizumab for treatment of advanced cervical cancer in combination with chemotherapy. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 15, 2014 Category: American Health Source Type: news

Avastin Approved for Late-Stage Cervical Cancer
More than 4,000 women projected to die this year from the disease (Source: WebMD Health)
Source: WebMD Health - August 15, 2014 Category: Consumer Health News Source Type: news

Avastin Approved for Late-Stage Cervical Cancer
More than 4,000 women projected to die this year from the disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 15, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Roche says US approves Avastin drug to treat cervical cancer
ZURICH (Reuters) - Swiss drugmaker Roche said on Friday the U.S. Food and Drug Administration (FDA) had approved the use of its Avastin cancer drug in combination with chemotherapy to treat advanced cervical cancer. (Source: Reuters: Health)
Source: Reuters: Health - August 15, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Media News)
Source: Roche Media News - August 15, 2014 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix. (Source: Roche Investor Update)
Source: Roche Investor Update - August 15, 2014 Category: Pharmaceuticals Source Type: news

FDA OKs Bevacizumab (Avastin) for Late-Stage Cervical CancerFDA OKs Bevacizumab (Avastin) for Late-Stage Cervical Cancer
The new indication for bevacizumab includes patients with cervical cancer that is persistent or recurrent. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Avastin Approved for Late-Stage Cervical Cancer
More than 4,000 women projected to die this year from the disease (Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - August 15, 2014 Category: Cancer & Oncology Source Type: news

FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer
The U.S. Food and Drug Administration today approved a new use for Avastin (bevacizumab) to treat patients with persistent, recurrent or late-stage (metastatic) cervical cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 14, 2014 Category: American Health Source Type: news

Second Turkish Man Pleads Guilty to Smuggling Fake Cancer Drugs
A second Turkish citizen pleaded guilty in U.S. federal court to smuggling misbranded and adulterated cancer drugs into the U.S., including a version of the cancer drug Avastin that isn't approved for U.S. sale. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 13, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Roche’s Avastin receives EU approval for recurrent ovarian cancer treatment
The European Commission has given approval to Roche to use Avastin (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin chemotherapy to treat women with recurrent ovarian cancer, which is resistant to platinum-co… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 8, 2014 Category: Pharmaceuticals Source Type: news

Avastin (Bevacizumab) Approved in EU for Type of Ovarian CancerAvastin (Bevacizumab) Approved in EU for Type of Ovarian Cancer
Roche said that the European Commission approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy in women with recurrent ovarian cancer resistant to platinum-containing chemotherapy. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 7, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Roche says Avastin approved in EU for type of ovarian cancer
ZURICH (Reuters) - Roche said on Wednesday that European regulators approved its drug Avastin as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Reuters: Health)
Source: Reuters: Health - August 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer
Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Roche Media News)
Source: Roche Media News - August 6, 2014 Category: Pharmaceuticals Source Type: news

EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer
Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - August 6, 2014 Category: Pharmaceuticals Source Type: news